You are here

Share:

Search Technologies

Showing 1-20 of 407 results found

Nanobodies Neutralizing Lassa Virus

The National Cancer Institute (NCI) seek parties interested in collaborative research and/or licensing to further develop neutralizing nanobodies targeting Lassa virus as a possible treatment of Lassa virus infections.

Therapeutics Against Pathogenic Coronaviruses

The Eunice Kennedy Shriver National Institute of Child Health and Human Development seeks research co-development partners and/or licensees to further develop and commercialize PIKfyve phosphatidyl linositol kinase inhibitors for the treatment of pathogenic coronaviruses.

Tamperless Tensor Elastography Imaging

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of tamperless tensor elastography imaging in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications.

Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data

Extracellular vesicles (EVs) are lipid spheres released from cells. EVs contain proteins that can serve as diagnostic biomarkers indicating the cell state at time of release. Improved detection and phenotyping of EVs and their protein cargo could lead to better cancer diagnostic and prognostic tests, as well as improved therapeutic uses. The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a software package that performs high-throughput multi-dimensional analysis of EV biomarkers.

Levonorgestrel Butanoate Formulation and Methods Relating Thereto

The National Institute of Child Health and Human Development (NICHD) seeks licensees and/or research co-development partners for the development of an injectable contraceptive for women with a pharmaceutical formulation containing levonorgestrel butanoate (LB), a steroidal progestin.

Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of diffusion tensor distribution imaging (DTD-MRI) in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications.

Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking

Impairment of cell motility and membrane trafficking can result in enhanced cell proliferation and survival and increased migration and invasion leading to cancer. Several proteins involved in cell motility and membrane trafficking have been shown to be dysregulated in various cancers. Animal models that facilitate the study of roles of these proteins in vivo are therefore required. The National Cancer Institute (NCI) seeks licensees for Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking

Optical Configuration Methods for Spectral Scatter Flow Cytometry

Scientists at the National Cancer Institute (NCI) seek licensees or co-development partners for a multispectral detection method capable of discriminating different Molecular NanoTag components. The capacity to discriminate further increases the sensitivity of detection for NanoTag molecules. Adaptations of this technology could also apply to incorporate spectral scatter detection in other cytometric and microfluidic systems.

Molecular Nanotags for Detection of Single Molecules

Researchers at the National Cancer Institute (NCI) developed novel molecular nanotags for single biological nanoparticle detection, resolution, and sorting, by flow cytometry. The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations to further advance this technology with extremely broad biomedical, biodefense, industrial, environmental, and other applications.

Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method

The National Eye Institute seeks research and co-development partners and/or licensees to: (1) advance the production and uses of the new RNA preparation method; (2) manufacture reagent kits for testing in patients with suspected COVID-19 and other DNA/RNA viruses, and (3) manufacture reagent kits for patient biomarker profiles and inherited disease diagnostics.

Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants

Researchers at the National Cancer Institute (NCI) developed a novel biophysical technique to purify extracellular vesicles (EVs) from contaminants such as proteins and unbound labels. The NCI seeks licensees and/or co-development research collaborations to further advance this technology for EV-based biomarkers and therapeutics to treat a wide range of diseases.

Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20

Researchers at the National Cancer Institute (NCI) developed improved monospecific and bicistronic chimeric antigen receptors (CARs) targeting CD19 and CD20. Importantly, CD19 and CD20 are highly expressed in diffuse large B-cell lymphoma, acute lymphoblastic leukemia and other B-cell lymphomas. These improved CARs can be useful in treating these diseases. NCI is seeking parties interested in the co-development or licensing of this invention for immunotherapy.

Cyclic Peptides as Non-Hormonal Male Contraceptive Agents and Methods of Use Thereof

The National Institute of Child Health and Human Development (NICHD) seeks licensees and/or research co-development partners for the development of cyclic peptides or peptidomimetic molecules as potential non-hormonal contraceptives for males. The cyclic peptides disrupt spermatogenesis by inhibiting the phosphorylation of GRTH/DDX25 (gonadotropin-regulated testicular helicase).

Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research licensees and /or co-development partners under a Cooperative Research and Development Agreement (CRADA) to advance preclinical and clinical development of methods to treat Alzheimer Disease using Carboxypeptidase E (CPE).

Pages